Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

Romeo-Gabriel Mihaila*

Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.

Case presentation: We present a female patient to which the disease has been monitored for 14 years, during which she has been treated with alpha-interferon, cladribine and  ituximab. The monitorization and conduct of such patients are discussed, and an analysis of the therapeutic possibilities at this stage is performed, which can be useful for physicians and researchers. 

Conclusion: An individual assessment of patient at diagnosis and during evolution is needed to determine which drug or drug combination is indicated and how many therapeutic lines are needed.

Keywords: BRAF V600E; Cladribine; Hairy cell; Leukemia; Rituximab

Published on: Aug 14, 2015 Pages: 4-7

Full Text PDF Full Text HTML DOI: 10.17352/2455-8591.000002
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat